Two Sigma Investments LP Has $10.72 Million Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Two Sigma Investments LP raised its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 12.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 273,352 shares of the biopharmaceutical company's stock after purchasing an additional 29,773 shares during the quarter. Two Sigma Investments LP owned approximately 0.36% of Xenon Pharmaceuticals worth $10,715,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Quarry LP bought a new position in shares of Xenon Pharmaceuticals in the fourth quarter valued at about $78,000. Blue Trust Inc. increased its position in Xenon Pharmaceuticals by 140.3% in the 4th quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company's stock valued at $95,000 after acquiring an additional 1,414 shares in the last quarter. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the fourth quarter worth approximately $101,000. KBC Group NV lifted its position in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company's stock worth $107,000 after purchasing an additional 780 shares in the last quarter. Finally, Magnetar Financial LLC bought a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at approximately $210,000. Institutional investors and hedge funds own 95.45% of the company's stock.

Xenon Pharmaceuticals Stock Performance

NASDAQ:XENE traded down $0.30 during trading hours on Friday, hitting $28.74. The stock had a trading volume of 227,284 shares, compared to its average volume of 533,725. The business's 50 day moving average is $33.13 and its 200-day moving average is $37.13. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -10.21 and a beta of 1.21. Xenon Pharmaceuticals Inc. has a one year low of $26.74 and a one year high of $46.00.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.07. The business had revenue of $7.50 million for the quarter, compared to analyst estimates of $1.64 million. During the same period in the previous year, the business posted ($0.62) EPS. On average, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on XENE shares. Needham & Company LLC lowered their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Royal Bank of Canada decreased their price target on Xenon Pharmaceuticals from $58.00 to $55.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. Evercore ISI assumed coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price objective for the company. William Blair reaffirmed an "outperform" rating on shares of Xenon Pharmaceuticals in a research note on Monday, May 5th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on shares of Xenon Pharmaceuticals in a research report on Tuesday, February 11th. They set a "buy" rating and a $67.00 price target for the company. One equities research analyst has rated the stock with a sell rating and twelve have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $54.82.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.